Brehanna Edwards Compares Apixaban or Rivaroxaban in VTE
Brehanna Edwards, PGY-2 Health-System Pharmacy Administration and Leadership Resident at Ascension, shared on LinkedIn:
”Publication Alert
I’m excited to share that our latest work, “Rethinking lead-in strategies: evaluation of full vs. reduced dose factor Xa inhibitors in acute VTE,” has just been published in the Journal of Thrombosis and Thrombolysis.
This multicenter study across 29 hospitals examined whether patients with acute VTE who received prior therapeutic parenteral anticoagulation truly require a full lead-in period of apixaban or rivaroxaban.
Our findings suggest that a reduced lead-in strategy is not associated with increased risk of VTE recurrence or major bleeding, offering important real-world evidence to inform clinical decision-making.
Grateful for the collaborative effort behind this project and excited for the ongoing conversation about optimizing anticoagulation strategies in acute VTE care.”
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics
-
Nov 8, 2026, 11:45Sher-Lu Pai: Investigating Intracardiac Thrombosis and Its Management in Liver Transplantation
-
Nov 8, 2026, 11:25Mehmet Cilingiroglu: Navigating Anticoagulation Choices in Acute Coronary Syndrome PCI